What do systematic reviews say?

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 315 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1340 participants
  Moderate

Intervention not reported

The review found no eligible studies for this question.

• First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Postmastectomy radiotherapy (PMRT) vs no PMRT

• Post‐mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes 2023 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 229 participants
  Low

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 744 participants
  Moderate

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 362 participants
  Moderate

Active information provision vs control

• Information provision for stroke survivors and their carers 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 91 participants
  Low

Active information provision vs control

• Information provision for stroke survivors and their carers 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  Low

Bethanechol vs placebo

The review found no eligible studies for this question.

• Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Suprapubic catheterisation vs intermittent self‐catheterisation

The review found no eligible studies for this question.

• Postoperative interventions for preventing bladder dysfunction after radical hysterectomy in women with early‐stage… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Telerehabilitation vs no rehabilitation control

It is very uncertain whether telerehabilitation changes quality of life ‐ CAT compared with no rehabilitation control (very low certainty).

• Telerehabilitation for chronic respiratory disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 189 participants
  Very low

Telerehabilitation vs centre‐based (outpatient) pulmonary rehabilitation

Telerehabilitation showed no clear difference in quality of life ‐ CAT compared with centre‐based (outpatient) pulmonary rehabilitation (moderate certainty).

• Telerehabilitation for chronic respiratory disease 2021 · Cochrane Headline outcomes only
  MD 1.37
  2 studies · 224 participants
  Moderate

Chemmotherapy combined with biological therapy vs chemotherapy alone

Chemmotherapy combined with biological therapy showed no clear difference in quality of life (QoL) compared with chemotherapy (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.88 [0.74, 1.04]
  2 studies · 1154 participants
  Low

Electrical stimulation (plus standard care) vs sham‐ECT plus standard care

The review found no eligible studies for this question.

• Electrical stimulation for treating pressure ulcers 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise therapy vs psychological treatment

The review found no eligible studies for this question.

• Exercise therapy for chronic fatigue syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
• Exercise therapy for chronic fatigue syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Very low

Biofeedback vs hypnotherapy

The review found no eligible studies for this question.

• Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Biofeedback plus standard therapy vs usual care

The review found no eligible studies for this question.

• Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Biofeedback vs counseling

• Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 29 participants
  Very low